Anika Therapeutics Stock Shares Outstanding
| ANIK Stock | USD 25.97 0.40 1.56% |
Anika Therapeutics fundamentals help investors to digest information that contributes to Anika Therapeutics' financial success or failures. It also enables traders to predict the movement of Anika Stock. The fundamental analysis module provides a way to measure Anika Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anika Therapeutics stock.
The value of Common Stock Shares Outstanding is expected to slide to about 12.7 M. Anika | Shares Outstanding |
Anika Therapeutics Company Shares Outstanding Analysis
Anika Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Anika Therapeutics Shares Outstanding | 14.85 M |
Most of Anika Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anika Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Anika Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Anika Therapeutics is extremely important. It helps to project a fair market value of Anika Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Anika Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anika Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anika Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Anika Shares Outstanding Historical Pattern
Today, most investors in Anika Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anika Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Anika Therapeutics shares outstanding as a starting point in their analysis.
Anika Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Anika Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Anika Therapeutics has 14.85 M of shares currently outstending. This is 91.77% lower than that of the Biotechnology sector and 91.51% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 97.4% higher than that of the company.
Anika Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anika Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anika Therapeutics could also be used in its relative valuation, which is a method of valuing Anika Therapeutics by comparing valuation metrics of similar companies.Anika Therapeutics is currently under evaluation in shares outstanding category among related companies.
Anika Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0236 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 331.08 M | ||||
| Shares Outstanding | 14.85 M | ||||
| Shares Owned By Insiders | 3.25 % | ||||
| Shares Owned By Institutions | 94.31 % | ||||
| Number Of Shares Shorted | 811.11 K | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.75 X | ||||
| Price To Sales | 2.23 X | ||||
| Revenue | 166.66 M | ||||
| Gross Profit | 96.78 M | ||||
| EBITDA | (11.21 M) | ||||
| Net Income | (82.67 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 29.04 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 14.48 X | ||||
| Cash Flow From Operations | (1.79 M) | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | (5.64) X | ||||
| Price To Earnings To Growth | 2.23 X | ||||
| Target Price | 30.33 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 379.71 M | ||||
| Total Asset | 270.63 M | ||||
| Retained Earnings | 128.05 M | ||||
| Working Capital | 132.25 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
| Net Asset | 270.63 M |
About Anika Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anika Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Anika Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Anika Therapeutics' short interest history, or implied volatility extrapolated from Anika Therapeutics options trading.
Pair Trading with Anika Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Anika Stock
| 0.58 | ETON | Eton Pharmaceuticals Financial Report 9th of May 2024 | PairCorr |
| 0.56 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.54 | EVOK | Evoke Pharma | PairCorr |
| 0.48 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Anika Therapeutics Piotroski F Score and Anika Therapeutics Altman Z Score analysis. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Anika Stock analysis
When running Anika Therapeutics' price analysis, check to measure Anika Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anika Therapeutics is operating at the current time. Most of Anika Therapeutics' value examination focuses on studying past and present price action to predict the probability of Anika Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anika Therapeutics' price. Additionally, you may evaluate how the addition of Anika Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Anika Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (5.64) | Revenue Per Share 11.372 | Quarterly Revenue Growth 0.085 | Return On Assets (0.02) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.